Operator: And our next question comes from the line of Uy Ear with Mizuho Securities.
Uy Ear: I guess the first question is, David, are you kind of saying that the fourth quarter was perhaps the growth was driven more by the market growth? Or did you do something that’s different, I guess, to to have to have a quarter where, I guess, seasonally, it will be down, but it’s not. And I guess my second question is, what do you think of the short-acting toxin that Allergan, I guess, reported some data for Jeuveau PE .
David Moatazedi: Sure. I think on the third quarter, I think what we said is we saw the overall procedural volume tick positively year-on-year. Then we went into the quarter with that assumption that it would. I believe the leading market player has guided to the same thing, the market for rebound. So that was our assumption, and we’re pleased that it played out we did not expect our business to grow sequentially. We had anticipated, as we have with prior years that you generally see a slight step down in the third quarter and then a step back up in the fourth. So we were pleasantly surprised by the increase in demand for Jeuveau in the third quarter, and we attribute that to continued market penetration and share gains more than we do to the actual procedural volume increase in the quarter that we had already factored for.
Moving on to the additional toxins that are coming in the market. I don’t have a lot of color to give you on the bond ia.I’m curious better understand how happy would position a shorter-acting toxin. I think the Street has not had visibility to what longer-acting could be, perhaps what shorter acting might be in the end, again, I think we’re well positioned here. We have the only 900-kilodalt molecule side from the market leader in the category where the brand is positioned against the younger generation, which is the fastest-growing segment in this market and a cash pay positioning that enables us to help grow the top line for those practices while getting conscientious for the fact that these practices want to continue to drive profitability into the future as they see some of the higher ticket procedures start to see some stalling.
So I think overall, we’re very well positioned here, how we are the competitive set that may be coming down the road. But I’m certainly curious to hear how that product gets positioned.
Operator: Thank you for all of your questions. At this time, I would like to turn the call back over to David Moatazedi, Chief Executive Officer for Evolus. David?
David Moatazedi: Thank you, operator. In closing, the success of our long-term strategy is evident in the strong results of the third quarter and clearly demonstrates the continued above-market progress that Evolus team is achieving in driving brand awareness and capturing market share. With record quarterly revenue and all-time highs in key metrics, we continue to build momentum, outpacing both the underlying growth of our market as well as the competition. The final results of our extra-strength study this past week and the addition of the Evolysse line of dermal fillers beginning in 2025 and underlying our continuing efforts to build a strong and growing PD brand. With a healthy injectable market backdrop and a 70% expansion in our total addressable market directly attributable to the addition of a dermal filler line, we remain confident in our $700 million revenue target for 2028, which represents a 29% revenue CAGR.
